Thursday Feb 27
Anti-adhesion therapies for inflammatory bowel disease
A high proportion of patients with inflammatory bowel disease do not achieve clinical remission with the current therapies including mesalazine , immunossupresants and antibodies against tumor necrosis factor .
Applied Clinical Trials
Altheus Therapeutics completes treatment portion of ZA201, a Phase 2...
The primary endpoint of ZA201 is reduction in the Ulcerative Colitis Disease Activity Index at 6 weeks.
Altheus Therapeutics announces the USPTO has awarded the Zoenasa Patent for Oral Combination Therapy
Combination therapy patents are uncommon and under-appreciated in the pharmaceutical industry because the Patent Office requires surprising, unexpected, or synergistic benefits from combining active ingredients into a single formulation.